The Hong Kong government earlier introduced two oral drugs for the treatment of new coronary pneumonia and prescribed them to high-risk individuals to reduce the risk of hospitalization and death, but the actual data on the related drugs on the Omicron virus strain is still insufficient.
The University of Hong Kong conducted a study on the efficacy of oral drugs from February to April this year. Two drugs developed by the pharmaceutical companies Molnupiravi and Paxlovid for the treatment of new coronary pneumonia were taken at the early stage of hospital admission and had significant clinical efficacy and could reduce the risk of death. , and reduce the amount of virus in the body faster, which reduces the mortality rate by 52% and 66% respectively.
The findings have now been published in the internationally renowned scientific journal The Lancet Infectious Diseases.
The fifth wave of the epidemic broke out in Hong Kong at the beginning of this year, and the public medical system collapsed. It was not until the introduction of the first batch of oral antiviral drugs for COVID-19 in mid-March that the burden on the medical system was relieved.
From February to April this year, the University of Hong Kong studied the efficacy of oral drugs against the BA.2 virus strain, analyzed the data of hospitalized patients diagnosed with new coronary pneumonia in Hong Kong, and selected patients who were suitable for taking oral antiviral drugs to participate in the study.
The findings have now been published in the internationally renowned scientific journal The Lancet Infectious Diseases.
The study was divided into two groups: 1,856 patients who started taking Molnupiravir developed by the pharmaceutical company Merck & Co. Molnupiravi within two days of hospital stay and 1,856 patients in the control group; 890 patients with Nirmatrelvir-ritonavir and 890 control patients.
It does not include non-oxygen treatment inpatients, those who have been hospitalized for more than 3 days and those under the age of 18.
The study found that 150 of the 1,856 patients who took monupavir died, compared with 295 in the control group (ie, no drug), a 52% reduction in mortality; Thirty-two people died, compared with 92 in the control group, a 66 percent reduction in mortality.
As for severe cases, that is, the use of ventilators and admission to the intensive care unit. Due to the small number of people, there is no obvious evidence that drugs can reduce the progression to severe cases. However, taking monupavir and paciclovir orally can reduce the need for oxygen respectively. The risk of treatment was 31% and 27%.
In addition, the two drugs are also effective in reducing the amount of virus, which can reduce the amount of virus by 38%, and there has been a significant decrease within 5 days of taking the drugs.
Huang Jinghao, assistant professor at the Department of Pharmacology and Pharmacy, Faculty of Medicine, HKU, said that research has proved that the antiviral effect of oral antiviral drugs and the reduction of mortality in hospitalized patients with non-oxygen treatment of new coronary pneumonia during the Omicron epidemic are very effective. Use oral antiviral drugs as soon as possible in critically ill hospitalized patients.
He Bailiang: On October 18, the "Thousand Days of Anti-epidemic" will be welcomed. It is time to cancel the mandatory testing of safe travel and gathering restrictions | 76 buildings are listed in Shatin District, most of them are private buildings, and luxury residences such as Baguio Bay have increased by 3,569 confirmed cases by 6 More than 1,600 people died and stayed in the hospital. Some residents of the four institutions were infected. Zeng Qiyin agreed that the forced inspection of the building may not be effective in cutting the transmission chain. He advocated the source of investment and encouraged the injection of oral medicine. Oral medicine for the new crown｜Yiwen Diqing has several types of symptoms for the beneficiaries of the relaxation of prescription drugs and should seek medical treatment immediately